Possible consequences of a shortage of hydroxychloroquine for patients with systemic lupus erythematosus amid the COVID-19 pandemic

Journal of Rheumatology

Volumn 47, Issue 6, 2020, Pages 787-790

  Peschken, Christine A ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; TUMOR NECROSIS FACTOR;

ANXIETY DISORDER; COMORBIDITY; CONFUSION; CORONAVIRUS DISEASE 2019; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MANUFACTURE; EDITORIAL; EMOTIONAL STRESS; EPIDEMIC; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFECTION RISK; PANDEMIC; PATIENT COMPLIANCE; PERSONAL EXPERIENCE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; BETACORONAVIRUS; CORONAVIRUS INFECTION; FEMALE; MALE; RISK ASSESSMENT; UNITED STATES; VIRUS PNEUMONIA;

BETACORONAVIRUS; CORONAVIRUS INFECTIONS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PANDEMICS; PNEUMONIA, VIRAL; RISK ASSESSMENT; UNITED STATES;

EID: 85083188375     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.200395     Document Type: Editorial

References (43)

1. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): People who are at higher risk for severe illness. 2020. [Internet. Accessed April 8, 2020.] Available from: www.cdc. gov/coronavirus/2019-ncov/specific-groups/ people-at-higher-risk.html
2. American College of Rheumatology. COVID-19 frequently asked questions. 2020. [Internet. Accessed April 8, 2020.] Available from: www.rheumatology.org/Portals/0/Files/COVID-19-FAQs.pdf
3. Figueroa-Parra G, Aguirre-Garcia GM, Gamboa-Alonso CM, Camacho-Ortiz A, Galarza-Delgado DA. Are my patients with rheumatic diseases at higher risk of COVID-19? Ann Rheum Dis 2020 Mar 22 (E-pub ahead of print).
4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020 Feb 24 (E-pub ahead of print).
5. American College of Emergency Physicians. Guidelines for the treatment of people with COVID-19 disease. 2020. [Internet. Accessed April 8, 2020.] Available from: www.acep.org/ globalassets/images/Italian-guidelines-for-covid-19-google-translate.pdf.pdf
6. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev 2020 Mar 25 (E-pub ahead of print).
7. Khan S, Siddique R, Shereen MA, Ali A, Liu J, Bai Q, et al. The emergence of a novel coronavirus (SARS-COV-2), their biology and therapeutic options. J Clin Microbiol 2020 Mar 5. (E-pub ahead of print).
8. Griffin R. Hospitals stockpile drug Trump says could treat COVID-19. Bloomberg.com (serial on the Internet). 2020. [Internet. Accessed April 8, 2020.] Available from:: www.bloomberg.com/ news/articles/2020-03-20/hospitals-stockpile-malaria-drug-trump-says-could-treat-covid-19
9. U.S. Department of Health and Human Services. HHS accepts donations of medicine to Strategic National Stockpile as possible treatments for COVID-19 patients. [Internet. Accessed April 8, 2020.] Available from: www.hhs.gov/about/news/2020/03/29/ hhs-accepts-donations-of-medicine-to-strategic-national-stockpile-as-possible-treatments-for-covid-19-patients.html
10. Sawa T. Doctors face sanctions for prescribing unproven COVID-19 drugs to friends and family, regulators warn. CBC.ca [Internet. Accessed April 8, 2020.] Available from: www.cbc.ca/news/health/ sanctions-canadian-doctors-experimental-drugs-1.5511244
11. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20-8.
12. Costedoat-Chalumeau N, Leroux G, Piette JC, Amoura Z. Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment? Joint Bone Spine 2010;77:4-5.
13. Petri M. Lupus in Baltimore: Evidence-based 'clinical pearls' from the Hopkins Lupus Cohort. Lupus 2005;14:970-3.
14. McCormick KM. A concept analysis of uncertainty in illness. J Nurs Scholarsh 2002;34:127-31.
15. Cleanthous S, Newman SP, Shipley M, Isenberg DA, Cano SJ. What constitutes uncertainty in systemic lupus erythematosus and rheumatoid arthritis? Psychol Health 2013;28:171-88.
16. Johnson Wright L, Afari N, Zautra A. The illness uncertainty concept: a review. Curr Pain Headache Rep 2009;13:133-8.
17. Delis PC. Uncertainty and quality of life in systemic lupus erythematosus: a cross-sectional study. Rehabil Nurs 2019;44:2-10.
18. Urback R. COVID-19 could spark a mental-health tsunami. The Globe and Mail. 2020 March 24. [Internet. Accessed April 8, 2020.] Available from: www.theglobeandmail.com/opinion/ article-covid-19-could-spark-a-mental-health-tsunami
19. Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry 2020;7:e21.
20. Tisseverasinghe A, Peschken C, Hitchon C. Anxiety and mood disorders in systemic lupus erythematosus: current insights and future directions. Curr Rheumatol Rep 2018;20:85.
21. Morand EF. Systemic lupus erythematosus: stress and the onset of SLE. Nat Rev Rheumatol 2018;14:127-8.
22. Tosevski DL, Milovancevic MP. Stressful life events and physical health. Curr Opin Psychiatry 2006;19:184-9.
23. Postal M, Lapa AT, Sinicato NA, de Oliveira Pelicari K, Peres FA, Costallat LT, et al. Depressive symptoms are associated with tumor necrosis factor alpha in systemic lupus erythematosus. J Neuroinflammation 2016;13:5.
24. Pawlak CR, Witte T, Heiken H, Hundt M, Schubert J, Wiese B, et al. Flares in patients with systemic lupus erythematosus are associated with daily psychological stress. Psychother Psychosom 2003;72:159-65.
25. Peralta-Ramirez MI, Jimenez-Alonso J, Godoy-Garcia JF, Perez-Garcia M. The effects of daily stress and stressful life events on the clinical symptomatology of patients with lupus erythematosus. Psychosom Med 2004;66:788-94.
26. Jung JY, Nam JY, Kim HA, Suh CH. Elevated salivary alpha-amylase level, association between depression and disease activity, and stress as a predictor of disease flare in systemic lupus erythematosus: a prospective case-control study. Medicine 2015;94:e1184.
27. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324:150-4.
28. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998;7:80-5.
29. Aouhab Z, Hong H, Felicelli C, Tarplin S, Ostrowski RA. Outcomes of systemic lupus erythematosus in patients who discontinue hydroxychloroquine. ACR Open Rheumatol 2019;1:593-9.
30. Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:3284-90.
31. Mok CC, Penn HJ, Chan KL, Tse SM, Langman LJ, Jannetto PJ. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. Arthritis Care Res 2016;68:1295-302.
32. Costedoat-Chalumeau N, Amoura Z, Hulot JS, Aymard G, Leroux G, Marra D, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 2007;66:821-4.
33. Melles RB, Jorge AM, Marmor MF, Zhang Y, Choi HK. Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016. Clin Rheumatol 2018;37:1853-9.
34. Jallouli M, Galicier L, Zahr N, Aumaitre O, Frances C, Le Guern V, et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheum 2015;67:2176-84.
35. Lee JY, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS, et al. Association of polymorphisms of cytochrome p450 2d6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheum 2016;68:184-90.
36. Yeon Lee J, Lee J, Ki Kwok S, Hyeon Ju J, Su Park K, Park SH. Factors related to blood hydroxychloroquine concentration in patients with systemic lupus erythematosus. Arthritis Care Res 2017;69:536-42.
37. Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-COV-2. Int J Antimicrob Agents 2020;55:105923.
38. Liu LH, Fevrier HB, Goldfien R, Hemmerling A, Herrinton LJ. Understanding nonadherence with hydroxychloroquine therapy in systemic lupus erythematosus. J Rheumatol 2019;46:1309-15.
39. Costedoat-Chalumeau N, Galicier L, Aumaitre O, Frances C, Le Guern V, Liote F, et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 2013;72:1786-92.
40. Feldman CH, Collins J, Zhang Z, Subramanian SV, Solomon DH, Kawachi I, et al. Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. Semin Arthritis Rheum 2018;48:205-13.
41. Lee SG, Park EK, Park JH, Kweon SM, Kim YK, Kim GT. Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus. Lupus 2018;27:753-61.
42. Iudici M, Pantano I, Fasano S, Pierro L, Charlier B, Pingeon M, et al. Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease. Lupus 2018;27:265-72.
43. Cabral RTS, Klumb EM, Carneiro S. Patients opinion and adherence to antimalarials in lupus erythematosus and rheumatoid arthritis treatment. J Dermatolog Treat 2020;31:264-9.